The new Joint National Committee 8 (JNC-8) blood pressure guidelines were recently published, and there are some major changes from JNC-7. There are also differences between JNC-8 and hypertension guidelines created by major organizations in North America and around the world published from 2013 to the present. In the face of conflicting evidence, it is difficult for practicing clinicians to reconcile these differences and to incorporate new guidance into their practice. This commentary will identify similarities and differences between guidelines, provide some literature context in the areas of differing recommendations, and then provide advice to enhance patient care.
JamesPAOparilSCarterBL. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
2.
ChobanianAVBakrisGLBlackHR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
3.
WeberMASchiffrinELWhiteWB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14-26. doi:10.1111/jch.12237.
4.
ManciaGFagardRNarkiewiczK. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159-2219.
American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(suppl 1):s11-s66.
7.
WrightJTFineLJLacklandDT. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499-503.
8.
BeckettNSPetersRFletcherAE. Treatment of hypertension in patients 80 years or older (HYVET). N Engl J Med. 2008;358:1887-1898.
9.
Bejan-AngoulvantTSaadatian-ElahiMWrightJM. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens. 2010;28:1366-1372.
10.
BrisoulisAAgarwalVTousoulisDStefanadisC. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomized controlled trials. Heart. 2014;100:317-323.
11.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly (SHEP). JAMA. 1991;265:3255.
12.
OgiharaTSarutaTRakugiH. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study (VALISH). Hypertension. 2010;56:196-202.
13.
JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115-2127.
14.
DenardoSJGongYNicholsWW. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719-726.
15.
OgihuraTNakaoKFukuiT. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the candesartan antihypertensive survival evaluation inJapan (CASE-J) trial. Hypertens Res. 2008;31:1595-1601.
16.
VibeetiGWheeldonNM; for the MARVAL Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678.
17.
CoyleJDGardnerSFWhiteCM. The renal protective effects of angiotensin II receptor blockers in type-2 diabetes mellitus. Ann Pharmacother. 2004;38:1731-1738.
18.
ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA. 2002;288:2981-2997.
19.
DahlofBDevereuxRBKjeldsenSE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
20.
ThomasGMullasariAS. Atenolol in hypertension. J Assoc Phys India. 2009;57(suppl):22-25.
21.
BlackHRElliotWTGranditsG. Principal results of the Controlled Investigation of Cardiovascular End points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
22.
WhiteCM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998;18:588-599.
23.
AgodoaLYAppelLBakrisGL. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
24.
NakaoNYoshimuraAMoritaH. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-124.
